Effective April 1, 2026, changes will be made to the representative directors, multiple new organizations including the President\u2019s Office and Advanced Biopharmaceutical Research Institute will be established or restructured, and personnel changes for executives and executive officers will be implemented.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4552-20260226-01.pdf","jir_short_summary":"Effective April 1, 2026, changes will be made to the representative directors, multiple new organizations including the President\u2019s Office and Advanced Biopharmaceutical Research Institute will be established or restructured, and personnel changes for executives and executive officers will be implemented.","jir_summary":"### Overview of Changes in Representative Directors and Organizational Restructuring\nJCR Pharmaceuticals Co., Ltd. will implement changes in its representative directors effective April 1, 2026. Mr. Toru Ashida will assume the position of Chairman and Representative Director, Mr. Hiroyuki Sonoda will become President and Representative Director, and Mr. Shin Ashida will become Director and Founder. Additionally, the President\u2019s Office and Advanced Biopharmaceutical Research Institute will be newly established as organizations directly overseen by the President, while a Regenerative Medicine Research Institute will be established within the Research Division, strengthening and expanding the organization. The Sales Division, Business Development Division, Corporate Strategy Division, and Administrative Division will also undergo name changes and organizational reorganization aimed at improving management efficiency.\n\n### Executive, Executive Officer, and General Personnel Changes\nEffective April 1, 2026, personnel changes for directors and executive officers will be conducted. Mr. Andrea Spezzi will be promoted to Executive Director and Senior Executive Officer, and Mr. Hiroshi Honda will assume the roles of Senior Executive Officer, Head of the Administrative Division, and Director of the President\u2019s Office, among other executive changes. General personnel changes include replacements and promotions of department heads and office managers across the Sales Division, Research Division, Production Division, Business Development Division, Corporate Strategy Division, and Administrative Division to strengthen organizational management.","jir_financial_highlights":"Date of Change in Representative Directors: 2026-04-01 (Appointment\/Transfer)\nDate of Organizational Restructuring: 2026-04-01 (Multiple New Establishments\/Reorganizations)\nDate of Executive and Executive Officer Personnel Changes: 2026-04-01 (Multiple Changes)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #ExecutivePersonnel, #OrganizationalChange, #executive_change, #JapanStocks","jir_key_figures":"Date of Change in Representative Directors: 2026-04-01\nEstablishment of President\u2019s Office: 2026-04-01\nEstablishment of Advanced Biopharmaceutical Research Institute: 2026-04-01","jir_meta_title":"JCR Pharmaceuticals Announces Change in Representative Directors and Organizational Restructuring Effective April 1, 2026","jir_meta_description":"JCR Pharmaceuticals Co., Ltd. will implement changes in representative directors, establish the President\u2019s Office and Advanced Biopharmaceutical Research Institute, and make executive and executive officer personnel changes effective April 1, 2026.","jir_og_title":"JCR Pharmaceuticals Announces Changes in Representative Directors and Organizational Restructuring","jir_og_description":"Effective April 1, 2026, changes to representative directors, multiple new organizational establishments and restructurings, and executive personnel changes will be implemented. The latest developments aimed at strengthening JCR Pharmaceuticals\u2019 management structure.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-31565","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n